From PoC to Scale-up: Quality, Supply Chain and Compliance
Taking a biotech project from proof-of-concept to the first production batch is like changing both vehicle and playing field: you move from the laboratory, where you can “touch” every variable, to the plant, where the variables watch you and—if you have not anticipated them—punish you. The scale-up is not a multiplication of volumes: it is a consistency check between biology, engineering, quality and the supply chain. It works when science remains science and also becomes repeatable process, when quality is not a stamp but a strategy, when the supply chain stops being a list of suppliers and becomes risk architecture. This page explains how we build that consistency: from recipes to design space, from suppliers to batch of validation, from process control to documentation that withstands an inspection.
From bench to plant: the leap that exposes false assumptions
At bench scale, a culture, an enzymatic reaction or a purification step may seem easy to control. At plant scale, there are new forces: mixing gradients, mass transfer, shear stress, inhibitor build-up, downtime that did not exist in the laboratory. This is why scale-up starts before of the first large vessel: with an experimental design (DoE) that maps critical variables and identifies the Critical Process Parameters (CPP) that govern the Critical Quality Attributes (CQA) of the product. We are not looking for the illusion of controlling everything; we are looking for a project space (design space) in which the process remains stable even when real-world conditions fluctuate.
The key step is accepting that the elegance of the PoC matters less than a stability curve. If a result fails when we double the volume or change agitation, it was not a result: it was a fragile equilibrium, good enough for a slide. Scale-up separates ideas that withstand reality from narratives that do not.
Quality by Design: quality designed in, not added after production
The quality is not added at the end. It is designed. The Quality by Design (QbD) is the discipline that turns the recipe into control strategy: we identify CQAs (purity, activity, potency, impurity profile, stability), identify the CPPs that influence them, and define operating ranges and we set up PAT (Process Analytical Technology) and in-process controls that detect drift before before they become waste. In practice, quality is achieved “upstream” with a robust process, not “downstream” with stricter testing.
The real test is the comparability: if we change scale, equipment or site, does the product remain “the same” within demonstrable margins? This is where QbD pays off: having models, data and pre-specified limits makes comparison technical rather than ideological. Without these foundations, every change becomes a chaotic mini-development programme.
Explore the topics
Validation and qualification: putting the process under oath
Before declaring “we are ready”, you need to go through the qualifications: URS (what is actually needed), DQ (the plant design meets the requirements), IQ (is installed as intended), OQ (works in all modes), PQ (produces under realistic conditions). Then come the PPQ (Process Performance Qualification): consecutive batches demonstrating that the routine holds up, not just on a good day. It is not bureaucracy: it is how the team learns to trust itself and how inspectors understand that you are not improvising.
Among the “non-glamorous” but decisive validations are the cleaning validation (avoid carry-over and cross-contamination), the stability real (not merely accelerated), the data integrity for electronic systems (the well-known ALCOA+), the analytical method qualification that measure what you say you want to control. Without these building blocks, scale-up is a house of cards.
Raw materials and suppliers: the supply chain as a process variable
In biotech, the raw material is never neutral. Even when they have the same name, two batches can “behave” differently in your process. The supply chain then it becomes part of the process: technical specifications that genuinely matter, CoA that actually say something rather than merely “OK”, audit of those who perform critical work for you, dual-sourcing where possible, plans for contingency for what is unique. If you realise too late that a nutrient behaves differently depending on the supplier, you do not have a supply chain: you have a deviation generator.
Logistics—cold chain, thermal mapping, transport times and conditions—does the rest. A process that at bench scale “did not suffer” from time may degrade at plant scale during the wrong hour of waiting or in the warmest corridor. Here, “GMP” is not an abstract acronym: it means recognising that biology has memory and that every step leaves a trace.
Documentation and systems: if it is not written down, it did not happen
Scale-up rewards those who know how to document. Living procedures, SOP understandable, forms that collect the data that are needed, not thousands of useless fields. Electronic systems must be validated (computer system validation), access is role-based, and the audit trail is readable and actively used, not merely present. In production, decisions are made on integrity-assured data: if a number can be rewritten without leaving a trace, that number has no value. The traceability must survive shift changes, night-time operations and the department head’s holiday week.
From science to contract: when the product meets the numbers
Scale-up is also economics. Yield, the rate of off-spec, batch release times, energy per unit of product, percentage of rework: these are figures that feed standard costs and business plan. If they worsen, even the most perfect audit will not save the project. This is why we measure and discuss early capex and opex: what does that bioreactor really cost in terms of downtime avoided? what does a tighter specification cost in terms of defects prevented? Technical choices become choices about margin when KPIs speak a single language.
“Change” is not an incident: it is part of the job
No scale-up remains unchanged. The change control when well designed, allow improvement without losing control: it is defined what is “major” and what is “minor”, how impact on CQAs and the dossier is assessed, and when comparability, when document management is sufficient. Change is a metabolism: if the system rejects it, you get stuck; if you integrate it well, you grow.
How Technoscience supports the PoC → scale-up phase
We do not arrive with a magic wand; we arrive with a method. We reconstruct the PoC by separating robust results from unstable sensitivities, set up targeted DoE, define CQAs and CPPs with the team, and help build design space and control strategy, we jointly design the PPQ that make sense for your product and regulatory pathway. On the supply chain, we map critical materials, dual-sourcing and risks; on compliance, we align the QMS, information systems and data integrity. Together with you, we prepare the technical history that will also become economic history when you speak with investors, banks and customers.
How to enter the Technoscience ecosystem (without losing months)
The first step is a PoC → scale-up fit check: product you want to take into the plant, technical status of the process (PoC, pilot, PPQ), available data on yield, stability and robustness, critical issues relating to quality, supply chain and compliance, resources and timelines. In a short call, we reconstruct the process, separate what is solid from what is still “slideware”, and propose a possible biotech industrialisation roadmap: targeted DoE, Quality by Design, control strategy, PPQ plan, map of critical materials and suppliers, CAPEX/OPEX impacts, and a roadmap for GMP and data-integrity compliance.
If the framework is sound, we produce an operational plan that does not leave quality, supply chain or regulatory considerations behind. If serious gaps emerge, we make them explicit and—where possible—indicate how to close them before committing plants, budgets and reputation.
Choose Technoscience!
If you are taking a biotech process or product from PoC to scale-up or need to reach the first GMP batch, use this form to request a PoC → scale-up fit check. In a short call, we analyse: development status (laboratory, pilot plant, PPQ), known CPPs and CQAs, plant constraints, materials and suppliers, QMS maturity and available data (batch records, stability studies, cleaning, validations). If the foundation is solid, we design a scale-up roadmap together, with technical steps, qualifications, PPQ, supply plans and key economic figures. If key elements are missing, we say so immediately: it is better to strengthen the process, data or supply chain now than to discover their limitations at the first inspection or with the first customer.
Frequently Asked Questions
The questions you ask us most often
It means that you decide before how quality will arise from the process: identify which product attributes matter (CQA), which process parameters govern them (CPP), which range keep everything within a project space robust. You implement PAT and in-process controls to detect drift and projects comparability and plans for validation consistent across changes in scale, site or equipment. Quality is not the release test: it is the process capability to repeat consistently.
Start with the critical materials and from the high-risk phases: define specifications that genuinely measure what you need (not “out of habit”), select and qualification suppliers through targeted audits, implement a dual-sourcing real, logistics map and cold chain with data, not hypotheses. Integrate quality and procurement: if procurement changes a supplier solely on price without understanding the effects on the process, you are buying deviations in the catalogue.